ArticleFrontiers in pharmacology2026

Cost-effectiveness of pembrolizumab plus weekly paclitaxel for PD-L1-positive platinum-resistant recurrent ovarian cancer in the United States and China.

Feng Xuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.